Erin Newburn, MS, PhD

About Erin Newburn, MS, PhD

Erin joined Personalis as a Field Application Scientist in 2013 with research experience in the areas of molecular biology, genetics, and biotechnology.  As the Senior Field Applications Manager, Erin’s team has global responsibility for providing both pre and post-sale technical support for the Personalis ACE Cancer Portfolio. She completed her postdoctoral training at the National Institute of Mental Health (NIMH) investigating candidate susceptibility genes for major psychiatric illnesses. Erin received her Ph.D. from the Ohio State University in Integrated Biomedical Science as a Presidential Fellow.
23 Jul, 2018

Five unanswered questions regarding personalized neoantigen cancer vaccines

Erin Newburn, MS, PhD Associate Director, Field Applications Scientist Five unanswered questions regarding personalized neoantigen cancer vaccines  From data presented at both AACR and ASCO in the past months, amazing progress continues to be made in the development of neoantigen vaccines.  As we marvel at the growth and big steps [...]

5 Mar, 2018

Understanding the role of HLA in Cancer Immunotherapy

Erin Newburn, MS, PhD Associate Director, Field Applications Scientist Understanding the role of Human Leukocyte Antigen in Cancer Immunotherapy The Flagpole MHC (major histocompatibility complex), also known as HLA (human leukocyte antigen) is the entire set of genes that code for proteins involved in antigen presentation.  Very simply, you could [...]

29 Nov, 2017

Ethnic disparities in precision genomics

The premise of the right drug for the right patient at the right time is critical for indications from cardiovascular and infectious disease to the latest immuno-oncology strategies.  It’s imperative to comprehend which patient will derive benefit from ...

30 Oct, 2017

Refining neoantigen load

Tumor mutational burden (TMB) has now been established as a positive predictive biomarker of response to immune checkpoint inhibitors with more studies demonstrating correlations between the overall mutational landscape and clinical benefit ...

22 Aug, 2017

Resistance to immunotherapy: The elusive routes of immune escape

Achieving a durable clinical response is the ultimate goal in immuno-oncology clinical trials. With immunotherapies showing long-lasting, unprecedented responses in cancer indications such as melanoma and Non-Small Cell Lung Cancer (NSCLC), these immune-boosting drugs seem to be displaying genuine advances in attaining significant and sustained response rates.

8 May, 2017

Is timing everything?

Unlike targeted therapies, there tends to be general agreement that it is unlikely that a single predictive biomarker in tumor biopsies will be found for determining response to immunotherapies.

Go to Top